Predictive Factors for Failure of Methotrexate Treatment of Cervical Pregnancy.
- Author:
Jae Sung LEE
1
;
Ja Young GWON
;
Eun Hee AN
;
Jae Hak LIM
;
Jin Bum JANG
;
Jung Yeon KIM
;
Sang Wook BAE
;
Gyung Joo LEE
Author Information
1. Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Cervical pregnancy;
methotrexate
- MeSH:
Chorionic Gonadotropin;
Female;
Humans;
Injections, Intramuscular;
Methotrexate*;
Parity;
Peritoneal Cavity;
Pregnancy*;
Risk Factors
- From:Korean Journal of Obstetrics and Gynecology
2001;44(1):134-138
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The use of methotrexate for the treatment of cervical pregnancy is now common practice. Our study was performed to determine the risk factors when the primary methotrexate treatment of cervical pregnancy was failed. METHODS: From January 1985 to December 1999, we studied 32 women with cervical pregnancies who were treated with methotrexate intramuscularly according to a repeated intramuscular injections protocol. For evaluation of the efficacy of therapy, pretreatment serum concentrations of human chorionic gonadotropin, the size of the gestational mass, fetal cardiac activity, and the presence of fluid in the peritoneal cavity were measured. This findings were analyzed and compared by means of the chi-square test, Fisher exact test, and student's t-test between the success and failure. RESULTS: There was no relation between the women's age, parity, the size of the conceptus, or the presence of fluid in the peritoneal cavity and the efficacy of treatment. A cervical pregnancy that presented with a serum human chorionic gonadotropin concentration of >or= 10,000mIU/ml, fetal cardiac activity was considered to be associated with a higher failure rate of primary methotrexate treatment. CONCLUSION: Among cervical pregnancies, a high serum human chorionic gonadotropin concentration and fetal cardiac activity were the important factors associated with failure of treatment with methotrexate.
